retatrutide phase 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Severe Obesity Trial Shows

They promote significant weight loss, improve lipid profiles, and reduce cardiovascular events, making them valuable for comprehensive care

For the full efficacy picture on each medication, see our semaglutide statistics report and tirzepatide statistics report for 2026

One study by Daniel et al demonstrated that liraglutide impaired keratinocyte inflammatory signals by activating AMP-activated protein kinase (AMPK), leading to reduced production of pro-inflammatory cytokines such as TNF- and IL-6

PlexusDx Precision Peptide Genetic Testing identifies your unique pathway sensitivity, allowing clinicians to design a weaning timeline that matches your biology rather than applying a one-size-fits-all schedule